126 related articles for article (PubMed ID: 8314539)
1. Enhancement of antiproliferative effect of cis-diamminedichloroplatinum(II) by clomiphene and tamoxifen in human ovarian cancer cells.
Kikuchi Y; Hirata J; Kita T; Imaizumi E; Tode T; Nagata I
Gynecol Oncol; 1993 Jun; 49(3):365-72. PubMed ID: 8314539
[TBL] [Abstract][Full Text] [Related]
2. [Circumvention of cisplatin resistant ovarian cancer cells by antiestrogens].
Ishii K; Kita T; Kudo K; Hisano A; Hirata J; Imaizumi E; Tode T; Kikuchi Y; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Jan; 47(1):19-26. PubMed ID: 7844449
[TBL] [Abstract][Full Text] [Related]
3. Modulation of sensitivity of human ovarian cancer cells to cis-diamminedichloroplatinum(II) by 12-O-tetradecanoylphorbol-13-acetate and D,L-buthionine-S,R-sulphoximine.
Hirata J; Kikuchi Y; Kita T; Imaizumi E; Tode T; Ishii K; Kudoh K; Nagata I
Int J Cancer; 1993 Sep; 55(3):521-7. PubMed ID: 8375936
[TBL] [Abstract][Full Text] [Related]
4. Effects of melatonin on the proliferation and cis-diamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells.
Futagami M; Sato S; Sakamoto T; Yokoyama Y; Saito Y
Gynecol Oncol; 2001 Sep; 82(3):544-9. PubMed ID: 11520153
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.
Kudoh K; Kikuchi Y; Hiramatsu H; Hirata J; Yamamoto K; Kita T; Nagata I
Eur J Cancer; 1997 Jan; 33(1):122-8. PubMed ID: 9071911
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.
Qamar L; Davis R; Anwar A; Behbakht K
Gynecol Oncol; 2008 Sep; 110(3):425-31. PubMed ID: 18619662
[TBL] [Abstract][Full Text] [Related]
7. cis-Diamminedichloroplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtCl4(Rh-123)2: evidence for mitochondrial involvement.
Ara G; Kusumoto T; Korbut TT; Cullere-Luengo F; Teicher BA
Cancer Res; 1994 Mar; 54(6):1497-502. PubMed ID: 8137254
[TBL] [Abstract][Full Text] [Related]
8. [Potentiation of cisplatin sensitivity of cisplatin-resistant human ovarian cancer cell lines by L-buthionine-S,R-sulfoximine].
Kudoh K; Kita T; Hirata J; Ishii K; Hiramatsu H; Kikuchi Y; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Jun; 46(6):525-32. PubMed ID: 8040625
[TBL] [Abstract][Full Text] [Related]
9. Growth-inhibitory effects of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]-ethanamine-HCl combined with cisplatin on human ovarian cancer cells inoculated into nude mice.
Hiramatsu H; Kikuchi Y; Kudoh K; Kita T; Tode T; Nagata I
Jpn J Cancer Res; 1997 Oct; 88(10):1003-8. PubMed ID: 9414663
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
11. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
12. [Cytokinetic effects of cisplatin on cisplatin-resistant ovarian cancer cell lines].
Sasa H; Kikuchi Y; Hisano A; Ishii K; Nagata I; Kawai T; Aida S; Sugita M; Sugishita T; Tenjin Y
Hum Cell; 1992 Dec; 5(4):384-91. PubMed ID: 1304801
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Basu A; Weixel K; Saijo N
Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400
[TBL] [Abstract][Full Text] [Related]
14. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II).
Kikuchi Y; Hirata J; Hisano A; Tode T; Kita T; Nagata I
Gynecol Oncol; 1995 Jul; 58(1):11-5. PubMed ID: 7789875
[TBL] [Abstract][Full Text] [Related]
15. cis-Diamminedichloroplatinum-resistant cell lines derived from human epithelial ovarian carcinoma express increased susceptibility to angiogenesis inhibitor TNP-470.
Tamura M; Takakuwa K; Tanaka K
Gynecol Oncol; 2004 Feb; 92(2):530-6. PubMed ID: 14766244
[TBL] [Abstract][Full Text] [Related]
16. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles.
Devalapally H; Duan Z; Seiden MV; Amiji MM
Clin Cancer Res; 2008 May; 14(10):3193-203. PubMed ID: 18483388
[TBL] [Abstract][Full Text] [Related]
17. Non-steroid receptor-mediated antiproliferative activity of styrylpyrone derivative in human breast cancer cell lines.
Pihie AH; Stanslas J; Din LB
Anticancer Res; 1998; 18(3A):1739-43. PubMed ID: 9673398
[TBL] [Abstract][Full Text] [Related]
18. Possible mechanisms of resistance to cis-diamminedichloroplatinum (II) of human ovarian cancer cells.
Kikuchi Y; Iwano I; Miyauchi M; Kita T; Sugita M; Tenjin Y; Nagata I
Jpn J Cancer Res; 1990; 81(6-7):701-6. PubMed ID: 2119370
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
20. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
